 | | | | ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday. | | |
| | | CLEVELAND (Reuters) - A federal judge on Wednesday blocked an Ohio law due to take effect later this month that would criminalize abortions based on a Down syndrome diagnosis, ruling that it violates a woman's right to choose. | | |
| | | (Reuters) - South Dakota on Wednesday sued three major drugmakers, accusing them of deceptively marketing prescription opioids and contributing to a nationwide epidemic. | | |
| | | (Reuters Health) - Smokers may be more likely to develop hearing loss than nonsmokers, and the risk increases with each additional cigarette people smoke on a typical day, a Japanese study suggests. | | |
| | | (Reuters Health) - A pregnant woman who becomes ill from the Zika virus faces a 7 percent chance that her child will be born with birth defects, and that risk jumps to nearly 13 percent if she becomes ill during the first trimester, a new study conducted in French territories in the Americas has concluded. | | |
| | | (Reuters Health) - Patients with private health insurance often face high out-of-pocket fees for advanced imaging, a U.S. study suggests. | | |
| | | (Reuters Health) - When one-half of a couple embraces good health, there’s a higher likelihood that the other half will, too, a recent study suggests. | | |
| | | (Reuters Health) - Older women with breast cancer who live in United States territories are less likely than their peers in the continental U.S. to receive recommended care, a study suggests. | | |
| | | BRUSSELS (Reuters) - Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug at a hearing on Tuesday. | | |
| | | (Reuters) - Health insurer UnitedHealth Group Inc on Tuesday named its board member and former GlaxoSmithKline Plc head Andrew Witty as chief executive of its pharmacy benefit unit, Optum, effective July 1. | | |
|
| |
